Cargando…

pLG72 levels increase in early phase of Alzheimer’s disease but decrease in late phase

pLG72, named as D-amino acid oxidase activator (although it is not an activator of D-amino acid oxidase demonstrated by later studies), in mitochondria has been regarded as an important modulator of D-amino acid oxidase that can regulate the N-methyl-D-aspartate receptor (NMDAR). Both oxidative stre...

Descripción completa

Detalles Bibliográficos
Autores principales: Lin, Chieh-Hsin, Chiu, Chih-Chiang, Huang, Chiung-Hsien, Yang, Hui-Ting, Lane, Hsien-Yuan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6744481/
https://www.ncbi.nlm.nih.gov/pubmed/31520071
http://dx.doi.org/10.1038/s41598-019-49522-1
_version_ 1783451379947274240
author Lin, Chieh-Hsin
Chiu, Chih-Chiang
Huang, Chiung-Hsien
Yang, Hui-Ting
Lane, Hsien-Yuan
author_facet Lin, Chieh-Hsin
Chiu, Chih-Chiang
Huang, Chiung-Hsien
Yang, Hui-Ting
Lane, Hsien-Yuan
author_sort Lin, Chieh-Hsin
collection PubMed
description pLG72, named as D-amino acid oxidase activator (although it is not an activator of D-amino acid oxidase demonstrated by later studies), in mitochondria has been regarded as an important modulator of D-amino acid oxidase that can regulate the N-methyl-D-aspartate receptor (NMDAR). Both oxidative stress in mitochondria and NMDAR neurotransmission play essential roles in the process of neurodegenerative dementia. The aim of the study was to investigate whether pLG72 levels changed with the severity of neurodegenerative dementia. We enrolled 376 individuals as the overall cohort, consisting of five groups: healthy elderly, amnestic mild cognitive impairment [MCI], mild Alzheimer’s disease [AD], moderate AD, and severe AD. pLG72 levels in plasma were measured using Western blotting. The severity of cognitive deficit was principally evaluated by Clinical Dementia Rating Scale. A gender- and age- matched cohort was selected to elucidate the effects of gender and age. pLG72 levels increased in the MCI and mild AD groups when compared to the healthy group. However, pLG72 levels in the moderate and severe AD groups were lower than those in the mild AD group. D-serine level and D- to total serine ratio were significantly different among the five groups. L-serine levels were correlated with the pLG72 levels. The results in the gender- and age- matched cohort were similar to those of the overall cohort. The finding supports the hypothesis of NMDAR hypofunction in early-phase dementia and NMDAR hyperfunction in late-phase dementia. Further studies are warranted to test whether pLG72 could reflect the function of NMDAR.
format Online
Article
Text
id pubmed-6744481
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-67444812019-09-27 pLG72 levels increase in early phase of Alzheimer’s disease but decrease in late phase Lin, Chieh-Hsin Chiu, Chih-Chiang Huang, Chiung-Hsien Yang, Hui-Ting Lane, Hsien-Yuan Sci Rep Article pLG72, named as D-amino acid oxidase activator (although it is not an activator of D-amino acid oxidase demonstrated by later studies), in mitochondria has been regarded as an important modulator of D-amino acid oxidase that can regulate the N-methyl-D-aspartate receptor (NMDAR). Both oxidative stress in mitochondria and NMDAR neurotransmission play essential roles in the process of neurodegenerative dementia. The aim of the study was to investigate whether pLG72 levels changed with the severity of neurodegenerative dementia. We enrolled 376 individuals as the overall cohort, consisting of five groups: healthy elderly, amnestic mild cognitive impairment [MCI], mild Alzheimer’s disease [AD], moderate AD, and severe AD. pLG72 levels in plasma were measured using Western blotting. The severity of cognitive deficit was principally evaluated by Clinical Dementia Rating Scale. A gender- and age- matched cohort was selected to elucidate the effects of gender and age. pLG72 levels increased in the MCI and mild AD groups when compared to the healthy group. However, pLG72 levels in the moderate and severe AD groups were lower than those in the mild AD group. D-serine level and D- to total serine ratio were significantly different among the five groups. L-serine levels were correlated with the pLG72 levels. The results in the gender- and age- matched cohort were similar to those of the overall cohort. The finding supports the hypothesis of NMDAR hypofunction in early-phase dementia and NMDAR hyperfunction in late-phase dementia. Further studies are warranted to test whether pLG72 could reflect the function of NMDAR. Nature Publishing Group UK 2019-09-13 /pmc/articles/PMC6744481/ /pubmed/31520071 http://dx.doi.org/10.1038/s41598-019-49522-1 Text en © The Author(s) 2019 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
spellingShingle Article
Lin, Chieh-Hsin
Chiu, Chih-Chiang
Huang, Chiung-Hsien
Yang, Hui-Ting
Lane, Hsien-Yuan
pLG72 levels increase in early phase of Alzheimer’s disease but decrease in late phase
title pLG72 levels increase in early phase of Alzheimer’s disease but decrease in late phase
title_full pLG72 levels increase in early phase of Alzheimer’s disease but decrease in late phase
title_fullStr pLG72 levels increase in early phase of Alzheimer’s disease but decrease in late phase
title_full_unstemmed pLG72 levels increase in early phase of Alzheimer’s disease but decrease in late phase
title_short pLG72 levels increase in early phase of Alzheimer’s disease but decrease in late phase
title_sort plg72 levels increase in early phase of alzheimer’s disease but decrease in late phase
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6744481/
https://www.ncbi.nlm.nih.gov/pubmed/31520071
http://dx.doi.org/10.1038/s41598-019-49522-1
work_keys_str_mv AT linchiehhsin plg72levelsincreaseinearlyphaseofalzheimersdiseasebutdecreaseinlatephase
AT chiuchihchiang plg72levelsincreaseinearlyphaseofalzheimersdiseasebutdecreaseinlatephase
AT huangchiunghsien plg72levelsincreaseinearlyphaseofalzheimersdiseasebutdecreaseinlatephase
AT yanghuiting plg72levelsincreaseinearlyphaseofalzheimersdiseasebutdecreaseinlatephase
AT lanehsienyuan plg72levelsincreaseinearlyphaseofalzheimersdiseasebutdecreaseinlatephase